Tay-Sachs Disease Treatment Market Size

Tay-Sachs Disease Treatment Market size was over USD 2.29 billion in 2023 and is anticipated to reach USD 4.71 billion by 2036, witnessing around 5.7% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of tay-sachs disease treatment is estimated at USD 2.39 billion.

The growth of the market can be attributed to the growing prevalence of the genetic disease, especially among infants. Tay-Sachs disease is caused by the mutation in HEXA genes, which results into loss of control over muscles. There is no known cure for this disease, therefore, the treatment is generally symptom-specific. Symptoms include exaggerated reactions to loud noises, seizures, loss of movement, vision, and hearing, accumulation of mucus in lungs, and others. The genetic mutation is witnessed specifically in a few communities, such as, eastern and central European Jewish communities, Ashkenazi Jews, certain French-Canadian communities, old order Amish community, and Cajun community, among others. According to the data by the U.S. National Library of Medicine, in this specific Jewish population, one out of every 27 members carry this gene, and one out of every 250-300 live births is affected by Tay- Sachs disease. Rising population of these high-risk communities, is anticipated to boost the market growth. Moreover, increasing investment in R&D activities, to develop new treatment methods to cure the genetic disorder, along with the emergence of new and better drugs used to treat symptoms and complications associated with the disease, are estimated to boost he tay-sachs disease treatment market growth.